Final answer:
Levalbuterol (Xopenex®) is the short-acting beta agonist that can be delivered via aerosol therapy for immediate relief of bronchospasm. Salmeterol (Serevent®) is incorrectly categorized here as it is a long-acting beta agonist used for maintenance therapy, not immediate relief. Tiotropium and dornase alpha are not beta agonists and are intended for other pulmonary conditions.
Step-by-step explanation:
The short-acting beta agonists that can be delivered via aerosol therapy includes levalbuterol (Xopenex®) and salbuterol (Serevent®). Levalbuterol is a medication that can be given through a nebulizer or as a metered-dose inhaler to treat or prevent bronchospasm in individuals with reversible obstructive airway disease. On the other hand, salmeterol is actually a long-acting beta agonist, not a short-acting one, and is typically not used for immediate relief. However, it can also be delivered via inhalation, but because of its long-acting nature, it's used for maintenance treatment rather than quick relief. In contrast, tiotropium (Spiriva®) and dornase alpha (Pulmozyme®) are not short-acting beta agonists; tiotropium is a long-acting muscarinic antagonist used for chronic obstructive pulmonary disease (COPD), and dornase alpha is an enzyme used to manage cystic fibrosis, neither of which are provided via aerosolized therapy to treat acute symptoms of asthma or bronchospasm.